Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5, 11-dione derivatives

Journal of Medicinal Chemistry

Volumn 51, Issue 12, 2008, Pages 3617-3629

  Ryckebusch, Adina ^a,b   Garcin, Deborah ^b   Lansiaux, Amélie ^c   Goossens, Jean François ^a   Baldeyrou, Brigitte ^c   Houssin, Raymond ^b   Bailly, Christian ^c,d   Hénichart, Jean Pierre ^b  

^a UNIV LILLE   (France)

^b Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; 8 (2 DIMETHYLAMINOETHOXY) 6 (2 DIMETHYLAMINOETHYL) 6H INDENO[1,2 C]ISOQUINOLINE 5,11 DIONE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GYRASE INHIBITOR; INDENO[1,2 C]ISOQUINOLINE 5,11 DIONE DERIVATIVE; INDENO[2,1 C]QUINOLIN 7 ONE DERIVATIVE; ISOQUINOLINE DERIVATIVE; MITOXANTRONE; MJ 238; MJ III 65; NSC 727357; QUINOLINE DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN HL 60; DRUG CYTOTOXICITY; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENCE; HUMANS; INDENES; ISOQUINOLINES; MITOXANTRONE; NUCLEIC ACID DENATURATION; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 45749087355     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800017u     Document Type: Article

References (37)

1. Padget, K.; Stewart, A.; Charlton, P.; Tilby, M. J.; Austin, C. A. An investigation into the formation of N-[2-(dimethylamino)ethyl]acridine-4- carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells. Biochem. Pharmacol. 2000, 60, 817-821.
2. Antony, S.; Kohlhagen, G.; Agama, K.; Jayaraman, M.; Cao, S.; Durrani, F. A.; Rustum, Y. M.; Cushman, M.; Pommier, Y. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol. Pharmacol. 2005, 67, 523-530.
3. Antony, S.; Agama, K. K.; Miao, Z. H.; Hollingshead, M.; Holbeck, S. L.; Wright, M. H.; Varticovski, L.; Nagarajan, M.; Morrell, A.; Cushman, M.; Pommier, Y. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}-propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol. Pharmacol. 2006, 70, 1109-1120.
4. Ewesuedo, R. B.; Iyer, L.; Das, S.; Koenig, A.; Mani, S.; Vogelzang, N. J.; Schilsky, R. L.; Brenckman, W.; Ratain, M. J. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J. Clin. Oncol. 2001, 19, 2084-2090.
5. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6, 789-802.
6. Champoux, J. J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 2001, 70, 369-413.
7. Wang, J. C. Cellular Roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 2002, 3, 430-440.
8. Giles, G. I.; Sharma, R. P. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med. Chem. 2005, 1, 383-394.
9. Takimoto, C. H.; Wright, J.; Arbuck, S. G. Clinical applications of the camptothecins. Biochim. Biophys. Acta 1998, 1400, 107-119.
10. Utsugi, T.; Aoyagi, K.; Asao, T.; Okazaki, S; Aoyagi, Y.; Sano, M.; Wierzba, K.; Yamada, Y. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn. J. Cancer Res. 1997, 88, 992-1002.
11. Byl, J. A.; Fortune, J. M.; Burden, D. A.; Nitiss, J. L.; Utsugi, T.; Yamada, Y.; Osheroff, N. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. Biochemistry 1999, 38, 15573-15579.
12. Fortune, J. M.; Velea, L.; Graves, D. E.; Utsugi, T.; Yamada, Y.; Osheroff, N. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition. Biochemistry 1999, 38, 15580-15586.
13. Kluza, J.; Lansiaux, A.; Wattez, N.; Mahieu, C.; Osheroff, N.; Bailly, C. Apoptotic response of HL-60 human leukemia cells to the antitumor drug TAS-103. Cancer Res. 2000, 60, 4077-4084.
14. Mizutani, H.; Tada-Oikawa, S.; Hiraku, Y.; Oikawa, S.; Kojima, M.; Kawanishi, S. Mechanism of apoptosis induced by a new topoisomerase inhibitor through the generation of hydrogen peroxide. J. Biol. Chem. 2002, 277, 30684-30689.
15. Torigoe, T.; Izumi, H.; Wakasugi, T.; Niina, I.; Igarashi, T.; Yoshida, T.; Shibuya, I.; Chijiiwa, K.; Matsuo, K.; Itoh, H.; Kohno, K. DNA topoisomerase II poison TAS-103 transactivates GC-box-dependent transcription via acetylation of Sp1. J. Biol. Chem. 2005, 280, 1179-1185.
16. Antony, S.; Jayaraman, M.; Laco, G.; Kohlhagen, G.; Kohn, K. W.; Cushman, M.; Pommier, Y. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res. 2003, 63, 7428-7435.
17. Kohlhagen, G.; Paull, K. D.; Cushman, M.; Nagafuji, P.; Pommier, Y. Protein linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol. Pharmacol. 1998, 54, 50-58.
18. Strumberg, D.; Pommier, Y.; Paull, K.; Jayaraman, M.; Nagafuji, P.; Cushman, M. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J. Med. Chem. 1999, 42, 446-457.
19. Marchand, C.; Antony, S.; Kohn, K. W.; Cushman, M.; Ioanoviciu, A.; Staker, B. L.; Burgin, A. B.; Stewart, L.; Pommier, Y. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol. Cancer Ther. 2006, 5, 287-295.
20. Cushman, M.; Jayaraman, M.; Vroman, J. A.; Fukunaga, A. K.; Fox, B. M.; Kohlhagen, G.; Strumberg, D.; Pommier, Y. Synthesis of new indeno[1,2-c] isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors. J. Med. Chem. 2000, 43, 3688-3698.
21. Xiao, X.; Antony, S.; Pommier, Y.; Cuhsman, M. On the binding of indeno[1,2-c]isoquinolines in the DNA-topoisomerase cleavage complex. J. Med. Chem. 2005, 48, 3231-3238.
22. Staker, B. L.; Feese, M. D.; Cushman, M.; Pommier, Y.; Zembower, D.; Stewart, L.; Burgin, A. B. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem. 2005, 48, 2336-2345.
23. Ioanoviciu, A.; Antony, S.; Pommier, Y.; Staker, B. L.; Stewart, L.; Cushman, M. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J. Med. Chem. 2005, 48, 4803-4814.
24. Okazaki, S.; Asao, T.; Wakida, M.; Ishida, K.; Washinosu, M.; Utsugi, T.; Yamada, Y. Novel Fused Indan Derivative and Pharmaceutically Acceptable Salts Thereof. PCT Int. Appl. WO 9532187 A1, 1995.
25. Morrell, A.; Placzek, M. S.; Steffen, J. D.; Antony, S.; Agama, K.; Pommier, Y.; Cushman, M. Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures. J. Med. Chem. 2007, 50, 2040-2048.
26. Nagarajan, M.; Morrell, A.; Fort, B. C.; Meckley, M. R.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings. J. Med. Chem. 2004, 47, 5651-5661.
27. Rastogi, S. N.; Bindra, J. S.; Anand, N. α-Methyldopa in a rigid framework: 3-amino-3-methyl-6,7-dihydroxy-3,4-dihydrocoumarins & 2-amino-6,7-dihydroxytetralin-2-carboxylic acids. Indian J. Chem. 1971, 9, 1175-1182.
28. Cushman, M.; Cheng, L. Stereoselective oxidation by thionyl chloride leading to the indeno[1,2-c]isoquinoline system. J. Org. Chem. 1978, 43, 3781-3783.
29. Morrell, A.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Synthesis of benz[d]indeno[1,2-b]pyran-5,11-diones: versatile intermediates for the design and synthesis of topoisomerase I inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 1846-1849.
30. Pommier, Y.; Covey, J. M.; Kerrigan, D.; Markovits, J.; Pham, R. DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucleic Acids Res. 1987, 15, 6713-6731.
31. Mincher, D. J.; Turnbull, A. Anthracene Derivatives as Anti-Cancer Agents. European Patent Specification EP1087935B1 [WO19999/ 065866], 2004.
32. Bridewell, D. J.; Finlay, G. J.; Baguley, B. C. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4- carboxamide (DACA). Anti-Cancer Drug Des. 2001, 16, 317-324.
33. Harker, W. G.; Slade, D. L.; Parr, R. L.; Feldhoff, P. W.; Sullivan, D. M.; Holguin, M. H. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukaemia cell line. Cancer Res. 1995, 55, 1707-1716.
34. Wells, R. D.; Larson, J. E.; Grant, R. C.; Shortle, B. E.; Cantor, C. R. Physicochemical studies on polydeoxyribonucleotides containing defined repeating nucleotide sequences. J. Mol. Biol. 1970, 54, 465-497.
35. Baguley, B. C.; Denny, W A.; Atwell, G. J.; Cain, B. F. Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the aniline ring. J. Med. Chem. 1981, 24, 170-177.
36. Pavlov, V.; Kong Thoo Lin, P.; Rodilla, V. Cytotoxicity, DNA binding and localisation of novel bis-naphthalimidopropyl polyamine derivatives. Chem.-Biol. Interact. 2001, 137, 15-24.
37. Bailly, C. DNA relaxation and cleavage assays to study topoisomerase I inhibitors. Methods Enzymol. 2001, 340, 610-623.